**Antinarcosepsy/Antihyperkinesis Agents**

**Therapeutic Class Code:** H8Q
**Therapeutic Class Description:** Antinarcosepsy/Antihyperkinesis Agents

<table>
<thead>
<tr>
<th>Medication</th>
<th>Generic Code Number(s)</th>
<th>NDC Number(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provigil, modafinil</td>
<td>26101, 26102</td>
<td></td>
</tr>
<tr>
<td>Nuvigil, armodafinil</td>
<td>98590, 98591, 98592, 36082</td>
<td></td>
</tr>
</tbody>
</table>

**Eligible Beneficiaries**

NC Medicaid (Medicaid) beneficiaries shall be enrolled on the date of service and may have service restrictions due to their eligibility category that would make them ineligible for this service.

NC Health Choice (NCHC) beneficiaries, ages 6 through 18 years of age, shall be enrolled on the date of service to be eligible, and must meet policy coverage criteria, unless otherwise specified. **EPSDT does not apply to NCHC beneficiaries.**

**EPSDT Special Provision: Exception to Policy Limitations for Beneficiaries under 21 Years of Age**

42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiaries under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed clinician). This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his/her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems. Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary’s physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary’s right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product, or procedure
a. that is unsafe, ineffective, or experimental/investigational.
b. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and/or other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary “to correct or ameliorate a defect, physical or mental illness, or a condition” [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary’s health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.
EPSDT and Prior Approval Requirements

EPSDT DOES NOT ELIMINATE THE REQUIREMENT FOR PRIOR APPROVAL IF PRIOR APPROVAL IS REQUIRED. Additional information on EPSDT guidelines may be accessed at http://www.ncdhhs.gov/dma/epsdt/. Coverage policies, service definitions, or billing codes shall be covered for NCHC beneficiaries.

Criteria

Approval will be considered as treatment to improve wakefulness for beneficiaries who

- Have a diagnosis of narcolepsy.
- Have excessive sleepiness associated with shift work sleep disorder.
- Require adjunct treatment for a diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) with concurrent use of continuous positive airway pressure (CPAP) if CPAP is the treatment of choice
- Have excessive fatigue associated with multiple sclerosis or myotonic dystrophy

Procedure

- Approval length one year.
- The maximum daily dose for modafinil is 400 mg.
- The maximum daily dose for armodafinil is 250 mg.

References


<table>
<thead>
<tr>
<th>Date</th>
<th>Change Log</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/04/2002</td>
<td>Criteria effective date</td>
</tr>
<tr>
<td>07/10/2007</td>
<td>Added requirement for CPAP and diagnosis of Obstructive Sleep Apnea/Hypopnea Syndrome</td>
</tr>
<tr>
<td>08/10/2009</td>
<td>Added coverage for Nuvigil</td>
</tr>
<tr>
<td>09/14/2011</td>
<td>Added coverage for diagnoses of Multiple Sclerosis and Myotonic Dystrophy</td>
</tr>
<tr>
<td>06/15/2012</td>
<td>Added modafinil and Nuvigil</td>
</tr>
<tr>
<td>09/13/2012</td>
<td>Added GCN 36082 for Nuvigil</td>
</tr>
<tr>
<td>05/22/2018</td>
<td>Added armodafinil</td>
</tr>
</tbody>
</table>